Scynexis (SCYX) Cash & Current Investments (2013 - 2026)
Scynexis (SCYX) posted Cash & Current Investments of $36.8 million for Q1 2026, up 72.22% on a QoQ basis from $21.3 million in Q4 2025, and down 32.24% year-over-year from $54.2 million in Q1 2025.
Scynexis (SCYX) Cash & Current Investments (2013 - 2026) Analysis & Trends
Scynexis' Cash & Current Investments history runs 14 years deep, the most recent figure standing at $36.8 million for Q1 2026.
- Quarterly Cash & Current Investments fell 32.24% year-over-year to $36.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.8 million (down 32.24% YoY) and the FY2025 annual result came in at $21.3 million, up 29.44% from the prior year.
- Cash & Current Investments was $36.8 million for Q1 2026 at Scynexis, up from $21.3 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $130.7 million in Q2 2024 and bottomed at $16.5 million in Q4 2024.
- A 5-year average of $59.8 million and a median of $44.8 million in 2025 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2023 — Cash & Current Investments surged 53.74% — and 2024, when it sank 72.38%.
- Scynexis' Cash & Current Investments stood at $73.5 million in 2022, then tumbled by 53.16% to $34.4 million in 2023, then sank by 52.12% to $16.5 million in 2024, then gained by 29.44% to $21.3 million in 2025, then surged by 72.22% to $36.8 million in 2026.
- Business Quant data shows SCYX's Cash & Current Investments at $36.8 million in Q1 2026, $21.3 million in Q4 2025, and $38.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 2.15 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Scynexis | 23.19 Mn | -13.57 Mn | - | 36.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.75 Mn |
| Dec 31, 2025 | 21.34 Mn |
| Sep 30, 2025 | 37.98 Mn |
| Jun 30, 2025 | 44.79 Mn |
| Mar 31, 2025 | 54.24 Mn |
| Dec 31, 2024 | 16.49 Mn |
| Sep 30, 2024 | 29.17 Mn |
| Jun 30, 2024 | 130.74 Mn |
| Mar 31, 2024 | 35.86 Mn |
| Dec 31, 2023 | 34.43 Mn |
| Sep 30, 2023 | 105.58 Mn |
| Jun 30, 2023 | 85.54 Mn |
| Mar 31, 2023 | 26.97 Mn |
| Dec 31, 2022 | 73.50 Mn |
| Sep 30, 2022 | 68.68 Mn |
| Jun 30, 2022 | 118.70 Mn |
| Mar 31, 2022 | 95.21 Mn |
| Dec 31, 2021 | 104.48 Mn |
| Sep 30, 2021 | 100.11 Mn |
| Jun 30, 2021 | 112.46 Mn |